TAR-210's Potential to Improve Outcomes in Intermediate-Risk NMIBC
Roger Li, MD, discusses what the future may hold for the use of TAR-210 for the treatment of patients with intermediate-risk non-muscle-invasive bladder cancer with susceptible FGFR alterations.